Group 1 - The "2025 Ophthalmic Medical Engineering Transformation Innovation Summit" was held in Hangzhou, focusing on the integration of medical and engineering innovations in the ophthalmic field [1][3] - The summit gathered industry experts and representatives to discuss the latest trends, challenges, and solutions in medical technology transformation, aiming to enhance the industrialization of medical technology achievements [1][2] - The Chinese ophthalmic medical device market has surpassed 200 billion yuan in 2024, with a high dependence on imported high-value consumables, reaching nearly 70% [2] Group 2 - The summit featured two core agendas: "Gathering Strengths and Coexistence" and "Chain Movement and Innovation," focusing on policy guidance and technological innovation in key areas such as ophthalmic technology development and cataract treatment [3] - Significant achievements in medical-engineering transformation were showcased, including the development of a new type of artificial lens and innovative non-invasive cataract treatment devices, supported by national key research projects [3][4] - The establishment of the "Medical-Engineering Integration Innovation Alliance" during the summit marks a new phase for clinical transformation projects in ophthalmology, supported by regulatory, industrial, and clinical collaboration [3][4] Group 3 - The summit emphasized the importance of collaboration between clinical medicine and engineering technology to overcome barriers and enhance the practical application of innovative ideas [4] - The company, Haohai Biological Technology, has developed a comprehensive transformation system covering raw material research, process innovation, clinical validation, and product transformation, aiming to enhance the quality of ophthalmic healthcare [4][5] - Haohai aims to accelerate the domestic production process of high-end technologies and provide comprehensive solutions for eye health, contributing to the "Healthy China 2030" initiative [5] Group 4 - The Shanghai Yangtze River Delta Medical Device Industry Development Promotion Association aims to promote innovation and development in the medical device industry, facilitating collaboration among enterprises, research institutions, and medical organizations [6] - Haohai Biological Technology is a leading company in the ophthalmic field, focusing on the research, development, and production of medical devices and pharmaceuticals using biomedicine and genetic engineering technologies [7] - The company has established a global presence and aims to enhance its competitive edge in the ophthalmic medical device market through innovation and integration of high-quality raw materials [7]

Core Insights - The Hainan Boao Lecheng International Medical Tourism Pilot Zone has achieved significant progress in its special drug and medical device policy, with 476 imported special drugs and devices as of April 30, 2025, including 175 drugs and 301 devices [1] Group 1: Policy Advantages - The Lecheng Pilot Zone has four core policy advantages: special drug and device policy, real-world research policy for drugs and devices, real-world research policy for medical insurance, and special operation policy for public hospitals [1] - The special drug and device policy allows the import and use of new drugs and devices that have not yet been approved in China, enabling patients to access the latest global medical innovations more quickly and conveniently [1] Group 2: Future Plans - The Lecheng Medical Supervision Bureau plans to focus on "medical" as the core and actively serve the introduction of special drugs and devices through a traceability platform, transitioning from passive approval to proactive service [2] - The zone aims to introduce a full range of special drugs and devices related to specific diseases and specialties, creating a comprehensive multidisciplinary center for disease management [2] - The plan includes expanding the entire industrial chain of special drugs and devices through real-world data research and medical-engineering transformation, positioning Lecheng as a new highland for drug and device research and development [2] Group 3: Regulatory Commitment - The special drug and device policy is regarded as Lecheng's "golden signboard," with a commitment to maintaining medical safety, ethical safety, and policy safety [3] - The Lecheng Medical Supervision Bureau will continue to support the application of special drugs and devices and real-world data research while strengthening regulation to ensure medical safety [3]

□ 河南日报客户端记者 杨凌河南日报社全媒体记者 刘慧丽 4月16日，郑州航空港"飞往"深圳这片充满活力与机遇的创新热土，与深圳迈瑞生物医疗电子股份有限 公司成功携手，正式签署全面合作协议。 此次签约是郑州航空港在生物医药领域招商引资的又一重要成果，将为区域医疗产业发展注入强大动 力，也为迈瑞医疗拓展市场、实现战略布局提供了新的机遇。 河南省人民政府副秘书长，郑州航空港经济综合实验区党工委副书记、管委会主任田海涛，深圳迈瑞生 物医疗电子股份有限公司党委书记林斗明亲临见证，共启深度合作新篇章。 据了解，迈瑞医疗是全球领先的医疗器械企业，在生命信息与支持、体外诊断、医学影像等领域占据重 要地位。签约前，郑州航空港相关人员参观考察了迈瑞医疗总部高端医疗设备展厅，对这位重要合作伙 伴有了更深层次的了解。 与之相匹配，郑州航空港作为河南经济发展的核心增长极，背靠河南超大规模医疗市场，集聚了全省优 质创新资源，正全力打造全球首个中西医结合的医学科学新城——中原医学科学城。 目前，中原医学科学城已吸引了西门子、飞利浦、中信健康等一大批优质企业落户，实现国药、华润、 通用等主营生物医药类央企全覆盖，全国医药工业百强覆盖率超3 ...